Journal
SMALL
Volume 13, Issue 46, Pages -Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/smll.201701817
Keywords
Alzheimer's disease; controlled release; metal ions; near-infrared light; upconversion
Categories
Funding
- 973 Project [2012CB720602]
- NSFC [21210002, 21431007, 21533008, 201402183]
- Project of Science and Technology Development Plan for Jilin Province [20150520004JH]
Ask authors/readers for more resources
Polyphenol compounds, such as curcumin, rutin, rifampicin, can inhibit A aggregation and decrease reactive oxygen species (ROS), and have received much attention in recent years for Alzheimer's disease (AD) treatment. However, the excess metal ions in amyloid plaque can chelate to polyphenol compounds. It significantly declines the efficacy of polyphenol compounds when used in the clinic. In this report, a near-infrared (NIR)-caged upconversion responsive system UCNP@SiO2@Cur/CQ is designed and synthesized to control drug sequential release by regulating NIR laser. When the system is irradiated at low intensity of the NIR laser, the caged metal chelator, clioquinol (CQ), is first released for removing free metal ions, which affects the efficacy of curcumin. Subsequently, the strongly caged curcumin is released with increasing the intensity of NIR light. In this way, the treatment efficacy of curcumin is improved. This NIR-caged drug release system can not only remove Cu2+ but also clean superfluous ROS. Therefore, developing controllable sequential drug releasing may provide clinical benefits of combination treatment of AD. To the best of our knowledge, this work reports for the first time that a sequentially controlled system can overcome the interference of metal ions on polyphenol compounds for AD treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available